Moderna (WBO:MRNA) Inventories, Raw Materials & Components : €149 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Moderna Inventories, Raw Materials & Components?

Moderna's inventories, raw materials & components for the quarter that ended in Dec. 2023 was €149 Mil.

Moderna's quarterly raw materials declined from Jun. 2023 (€468 Mil) to Sep. 2023 (€140 Mil) but then increased from Sep. 2023 (€140 Mil) to Dec. 2023 (€149 Mil).

Moderna's annual raw materials declined from Dec. 2021 (€770 Mil) to Dec. 2022 (€543 Mil) and declined from Dec. 2022 (€543 Mil) to Dec. 2023 (€149 Mil).

Moderna Inventories, Raw Materials & Components Historical Data

The historical data trend for Moderna's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Inventories, Raw Materials & Components Chart

Moderna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Raw Materials & Components

Get a 7-Day Free Trial

30.41

769.95

542.80

149.47

Moderna Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Inventories, Raw Materials & Components	Get a 7-Day Free Trial															542.80	443.65	467.96	139.61	149.47

Moderna Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

Moderna (WBO:MRNA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (WBO:MRNA) » Definitions » Inventories, Raw Materials & Components

Comparable Companies

Traded in Other Exchanges

MRNA:USA MRNA:Peru MRNA:Mexico 0QFd:UK 0A45:UK 0QF:Germany M1RN34:Brazil

Address

200 Technology Square, Cambridge, MA, USA, 02139

Website

https://www.modernatx.com

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.